PL1963302T3 - Polimorfy inhibitora c-Met/HGFR - Google Patents

Polimorfy inhibitora c-Met/HGFR

Info

Publication number
PL1963302T3
PL1963302T3 PL06820988T PL06820988T PL1963302T3 PL 1963302 T3 PL1963302 T3 PL 1963302T3 PL 06820988 T PL06820988 T PL 06820988T PL 06820988 T PL06820988 T PL 06820988T PL 1963302 T3 PL1963302 T3 PL 1963302T3
Authority
PL
Poland
Prior art keywords
polymorphs
met
hgfr inhibitor
hgfr
inhibitor
Prior art date
Application number
PL06820988T
Other languages
English (en)
Inventor
Jingrong Jean Cui
Michelle Bich Tran-Dube
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38123249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1963302(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL1963302T3 publication Critical patent/PL1963302T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL06820988T 2005-12-05 2006-11-23 Polimorfy inhibitora c-Met/HGFR PL1963302T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74267605P 2005-12-05 2005-12-05
PCT/IB2006/003383 WO2007066185A2 (en) 2005-12-05 2006-11-23 Polymorphs of a c-met/hgfr inhibitor
EP06820988A EP1963302B1 (en) 2005-12-05 2006-11-23 Polymorphs of a c-met/hgfr inhibitor

Publications (1)

Publication Number Publication Date
PL1963302T3 true PL1963302T3 (pl) 2013-06-28

Family

ID=38123249

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06820988T PL1963302T3 (pl) 2005-12-05 2006-11-23 Polimorfy inhibitora c-Met/HGFR

Country Status (19)

Country Link
US (1) US8217057B2 (pl)
EP (1) EP1963302B1 (pl)
JP (1) JP4663619B2 (pl)
KR (1) KR101146852B1 (pl)
CN (1) CN101326175B (pl)
AR (1) AR057964A1 (pl)
AU (1) AU2006323025B2 (pl)
CA (1) CA2632283C (pl)
DK (1) DK1963302T3 (pl)
ES (1) ES2402419T3 (pl)
IL (1) IL191971A (pl)
NZ (1) NZ568289A (pl)
PL (1) PL1963302T3 (pl)
PT (1) PT1963302E (pl)
RU (1) RU2387650C2 (pl)
SI (1) SI1963302T1 (pl)
TW (1) TWI389902B (pl)
WO (1) WO2007066185A2 (pl)
ZA (1) ZA200804374B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005020465D1 (de) 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
PL1959955T3 (pl) * 2005-12-05 2011-04-29 Pfizer Prod Inc Sposób traktowania nieprawidłowego wzrostu komórek
EP2265270A1 (en) * 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US8592448B2 (en) * 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2569315A1 (en) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
CN103052386B (zh) 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
EP2620140A1 (en) 2012-01-26 2013-07-31 ratiopharm GmbH Crizotinib containing compositions
DK2822953T5 (en) 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
WO2013181251A1 (en) 2012-05-29 2013-12-05 Ratiopharm Gmbh Crizotinib hydrochloride salt in crystalline
CN104603620B (zh) 2012-09-24 2018-02-23 文塔纳医疗系统公司 使用间变性淋巴瘤激酶(alk)作为标志物鉴定治疗响应性非小细胞肺癌的方法
WO2014115169A2 (en) * 2013-01-24 2014-07-31 Hetero Research Foundation Crizotinib solid dispersion
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
TWI831128B (zh) 2014-04-25 2024-02-01 日商中外製藥股份有限公司 以高用量含有４環性化合物的製劑
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016169030A1 (zh) * 2015-04-23 2016-10-27 正大天晴药业集团股份有限公司 吡啶胺化合物的富马酸盐及其晶体
US10259816B2 (en) 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
LT3458053T (lt) 2016-05-20 2022-02-25 Biohaven Pharmaceutical Holding Company Ltd. Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN108727337A (zh) * 2018-07-03 2018-11-02 无锡富泽药业有限公司 一种克唑替尼中间体的制备方法
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
US12186393B2 (en) 2019-08-02 2025-01-07 Onehealthcompany, Inc. Method of treating transitional cell carcinoma in a canine by administering lapatinib, wherein the carcinoma harbors a BRAF mutation
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023086671A1 (en) * 2021-11-15 2023-05-19 The Broad Institute, Inc. Compounds, compositions, and methods for inducing antimicrobial intracellular activity and for preventing and treating microbial infections

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JPH07109260A (ja) 1993-10-12 1995-04-25 Fuji Photo Film Co Ltd ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
WO2001000213A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
PL365238A1 (pl) * 2000-02-16 2004-12-27 Neurogen Corporation Podstawione arylopirazyny
CN1446202A (zh) * 2000-08-11 2003-10-01 卫材株式会社 2－氨基吡啶化合物及其作为药物的用途
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6992087B2 (en) * 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
DK1603570T5 (da) * 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
EP1786777A1 (en) * 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
ES2355923T3 (es) * 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
DE602005020465D1 (de) * 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
PL1959955T3 (pl) * 2005-12-05 2011-04-29 Pfizer Prod Inc Sposób traktowania nieprawidłowego wzrostu komórek

Also Published As

Publication number Publication date
CN101326175A (zh) 2008-12-17
EP1963302B1 (en) 2013-02-27
AU2006323025A1 (en) 2007-06-14
CN101326175B (zh) 2012-07-18
US20080293769A1 (en) 2008-11-27
TW200730522A (en) 2007-08-16
JP4663619B2 (ja) 2011-04-06
US8217057B2 (en) 2012-07-10
BRPI0619420A2 (pt) 2011-10-04
SI1963302T1 (sl) 2013-04-30
TWI389902B (zh) 2013-03-21
NZ568289A (en) 2011-06-30
HK1126477A1 (en) 2009-09-04
CA2632283C (en) 2011-06-21
IL191971A0 (en) 2011-08-01
IL191971A (en) 2013-05-30
WO2007066185A3 (en) 2008-01-24
JP2007153893A (ja) 2007-06-21
DK1963302T3 (da) 2013-04-02
PT1963302E (pt) 2013-04-09
KR101146852B1 (ko) 2012-05-16
ZA200804374B (en) 2009-12-30
AU2006323025B2 (en) 2012-07-05
AR057964A1 (es) 2007-12-26
RU2387650C2 (ru) 2010-04-27
KR20080074950A (ko) 2008-08-13
ES2402419T3 (es) 2013-05-03
CA2632283A1 (en) 2007-06-14
RU2008120338A (ru) 2010-01-20
WO2007066185A2 (en) 2007-06-14
EP1963302A2 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
ZA200804374B (en) Polymorphs of a C-MET/HGFR inhibitor
IL205756A0 (en) Polymorphs of a c-met/hgfr inhibitor
PL2089364T3 (pl) Związki pirydynonu
IL192395A0 (en) Modified lysine-mimetic compounds
IL183961A0 (en) Novel pyridine compounds
GB0504995D0 (en) Use of a compound
AP2007004171A0 (en) Novel compounds
GB0521244D0 (en) Benzamide compounds
EP1868612A4 (en) NOVEL CONNECTIONS
EP1868611A4 (en) NOVEL CONNECTIONS
AP2007004282A0 (en) Derivatives of A 1-phenyltriazole as antiparasiticagents
GB0504314D0 (en) Novel polymorph
ZA200705419B (en) Novel pyridine compounds
EP1957657A4 (en) BIOMARKER OF ENHANCED INTESTINAL FUNCTION
IL186301A0 (en) Hydromorphone polymorphs
IL186143A0 (en) Pro-drugs of n-thiazol-2yl-benzamide derivatives
GB0518494D0 (en) Thiazole compounds
EP1869026A4 (en) NEW CONNECTIONS
GB0514685D0 (en) A ntineoplastic compounds
ZA200707966B (en) Pro-drugs of n-thiazol-2yl-benzamide derivatives
GB0522829D0 (en) Use of a compound
GB0512626D0 (en) Inhibitor compounds
GB0503944D0 (en) Comparison of patterns
GB0517677D0 (en) Inhibitor compounds II
GB0608095D0 (en) Novel compounds A3